Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.
56 results about "Combination Product" patented technology
Filter
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
A product comprised of two or more regulated components, i.e., drug and device, biologic and device, that are physically, chemically, or otherwise combined or mixed and produced as a single entity; or two or more separate products packaged together in a single package or as a unit and comprised of drug and device products, device and biological products, or biological and drug products; or a drug, device, or biological product packaged separately that according to its investigational plan or proposed labeling is intended for use only with an approved individually specified drug, device, or biological product where both are required to achieve the intended use, indication, or effect and where upon approval of the proposed product the labeling of the approved product would need to be changed, e.g., to reflect a change in intended use, dosage form, strength, route of administration, or significant change in dose; or any investigational drug, device, or biological product packaged separately that according to its proposed labeling is for use only with another individually specified investigational drug, device, or biological product where both are required to achieve the intended use, indication, or effect.
The invention discloses a nucleic acidcombination product for detecting various respiratory pathogens, a kit containing the nucleic acidcombination product and a method. The nucleic acidcombination product comprises a primer pair and a probe, wherein the nucleotide sequences of the primer pair and the probe are respectively shown as SEQ ID NO: 1-21. According to the nucleic acid combination product, on the technical basis of Taqman fluorescent quantification, seven targets can be detected by one tube, so that the time and energy of operators are greatly shortened, and the nucleic acid combination product is convenient and rapid, is not easy to make mistakes, and is simpler and easier to understand in result interpretation.
Disclosed herein are drug delivery devices including catheter assemblies, infusion systems, pre-filled syringes, methods of use, combination products, kits of parts, and drug products with parts lists for independent sourcing, for use in the otic administration of a drug product to a subject in need thereof.
This invention relates to anti-CD40 antibodies or antigen-binding fragments thereof that specifically recognize and weakly activate CD40 molecules in humans, cynomolgus monkeys, and mice, as well as immunoconjugates, pharmaceutical compositions, and combination products comprising said anti-CD40 antibodies or antigen-binding fragments thereof. The invention also relates to nucleic acids encoding said anti-CD40 antibodies or antigen-binding fragments thereof and host cells comprising said nucleic acids, and methods for preparing said anti-CD40 antibodies or antigen-binding fragments thereof. Furthermore, the invention relates to the use of said anti-CD40 antibodies or antigen-binding fragments thereof in the prevention or treatment of tumors or infectious diseases in subjects.
To provide a smoking system that when a flavor generation article is inserted into a chamber, allows a user to easily feel arrival at an end of the chamber and to easily foresee that it will arrive at the end of the chamber.SOLUTION: When a resistance value when a flavor generation article is inserted into a storage part and a tip of the flavor generation article arrives at an end of the storage part, is insertion force A, and a ratio of a rear-half average resistance force to a front-half average resistance force is a first resistance ratio B, a smoking system satisfies A≤4.00 N and B>1.0, where the rear-half average resistance value is an average of resistance values from a midpoint between a prescribed position on an insertion end side of the storage part and an end of the storage part to the end of the storage part. and the front-half average resistance force is an average of resistance values from the prescribed position to a midpoint between the prescribed position and the end of the storage part.SELECTED DRAWING: Figure 16
The present invention relates to a method for evaluating the effectiveness of an aerosol (3) for pulmonary drug delivery, as well as inhaler devices (2, 2a, 2b, 2c, 2d), orally inhaled drugs (1), and drug / device combination products (7). [Solution] An inhaler device (2, 2a, 2b, 2c, 2d) can generate an aerosol (3), which contains aerosol particles (30) containing an orally inhaled drug (1). The method includes the steps of providing a computational lung model (Lmod) and a computational particle transport and deposition model (Pmod), calculating the spatial particle deposition distribution (Ddist) of discrete particles (30') based on a determined aerosol value (Aval) of an aerosol parameter (Apar), calculating the efficacy value (Eval) of an efficacy parameter (Epar) based on the spatial particle deposition distribution (Ddist), and using the efficacy value (Eval) to automatically evaluate the efficacy of the aerosol (3) for lungdrug delivery.
This application belongs to the field of molecular biology technology, specifically relating to nucleic acid combo products, kits for mycobacterial identification, and their applications. This application provides a nucleic acid combo product for mycobacterial detection, comprising one or more primer pairs with nucleotide sequences as shown in SEQ ID NO.1 to SEQ ID NO.244. This specific primer combination can simultaneously detect multiple mycobacteria and distinguish them down to the subspecies level. Through highly specific primer design, this nucleic acid combo product can achieve accurate identification of common clinical mycobacteria (including complex groups, species, and subspecies levels), with a detection sensitivity of 50-100 CFU / mL, significantly superior to the detection performance of existing technologies. Furthermore, the nucleic acid combo product of this application can not only identify the species of mycobacteria but also simultaneously detect drug resistance gene mutations, providing important evidence for the selection of clinical treatment regimens.
A pharmaceutical composition in a fixed-dose combination is described, comprising: a) a dofetilide component; and b) a mexiletine component; wherein the dofetilide component and the mexiletine component are physically separated from each other, and a method for treating or preventing atrial fibrillation or related symptoms in a subject by administering such pharmaceutical composition to a subject in need, and a method for preparing such a fixed-dosecombination product.
The application relates to the technical field of molecular biology detection, in particular to a nucleic acidcombination product for identifying respiratory tract pathogens, a PCR premix, a kit and a method. The nucleic acidcombination product comprises primer pairs and probes shown in SEQ ID NO: 1 to SEQ ID NO: 21. The primer pairs and the probes can be mixed with other reagents required by PCR, and then freeze-dried to prepare a freeze-dried ball. The freeze-dried ball is smooth and round in surface, and after a nucleic acid sample liquid to be detected is directly dropped into a PCR reaction tube containing the freeze-dried ball, machine detection can be carried out. The freeze-dried ball is not only beneficial to storage and transportation, but also convenient to operate. In particular, the effect of joint detection of target pathogens is good, and the detection sensitivity is also improved.
The present invention relates to a combination product comprising a Bcl-2 / Bcl-xL inhibitor and a chemotherapeutic agent, in particular a Bcl-2 / Bcl-xL inhibitor of formula I-A and homoharringtonine or an active derivative thereof, in free or pharmaceutically acceptable salt or solvate form. The invention also relates to the use of the aforementioned combination for the preparation of a medicament for the prevention and / or treatment of cancer, in particular of hematological malignancies, and to a method for the prevention and / or treatment of cancer, in particular of hematological malignancies, using the aforementioned combination.
The invention relates to the technical field of molecular biological detection, in particular to a nucleic acidcombination product, a PCR premixed solution, a kit and a method for identifying respiratory pathogens. The nucleic acidcombination product comprises a primer pair as shown in SEQ ID NO: 1 to SEQ ID NO: 21 and a probe. The primer pair and the probe combination can be mixed with other reagents required by PCR and then freeze-dried to prepare freeze-dried balls, the surfaces of the freeze-dried balls are smooth and round, nucleic acid sample liquid to be detected can be directly dropwise added into a PCR reaction tube filled with the freeze-dried balls and then can be detected on a machine, storage and transportation are facilitated, operation is convenient and fast, the combined detection effect of target pathogens is especially good, and the detection efficiency is high. And the detection sensitivity is also improved.
The invention relates to a composition for tumor local injection, a medical and mechanical combined product and application of the composition in preparation of a medicine for tumor local injection administration. The composition comprises an antitumor drug component, an immunologic adjuvant and a drug carrier. By means of the jet flow microneedle delivery device which is specially designed, tumor local drug delivery of anti-tumor drugs can be achieved, and the problem that the maximum drug dosage and the treatment effect are limited due to systemtoxicity in traditional intravenous drug delivery is solved. The high-concentration local administration of the composition provided by the invention not only improves the local treatment effect of tumors, but also can effectively generate tumor antigens. The tumor antigen generated in situ can be matched with an immunologic adjuvant in the composition to generate tumor specific immune cells on the premise that the immune system of a patient is not damaged due to the toxicity of a drug system, so that the immune response of the local part and the whole body of the patient to tumors is improved. Besides, in the subsequent treatment course after the initial treatment, only the composition of the immunologic adjuvant and the tumor specific polypeptide or the immunologic adjuvant can be given to maintain and enhance the established tumor specific immune response, and accumulated toxicity caused by repeated use of chemotherapeutic drugs is avoided.
The application relates to the technical field of molecular biology detection, in particular to a nucleic acidcombination product for identifying respiratory tract pathogens, a PCR premix, a kit and a method. The nucleic acidcombination product comprises a primer pair and a probe with sequences shown in SEQ ID NO: 1 to SEQ ID NO: 21. The nucleic acidcombination product comprises a primer pair and a probe for detecting target pathogens, and in the process of detecting multiple targets based on the same reaction system, cross-reactions can be avoided, and the interference of drugs can also be avoided. In addition, the nucleic acid combination product is suitable for preparing a freeze-dried reagent, and through the selection of a freeze-drying protective agent component, primer probe damage can be avoided, and the compatibility of multiple components can be improved.
The invention provides a liquefactioncombination product of a viscous biological sample, a nucleic acid detection kit and application of the liquefactioncombination product. The liquefied combination product of the viscous biological sample comprises a first component and a second component, the first component is prepared from the following components: 10 mmol / L to 100 mmol / L of acetylcysteine, 5 mmol / L to 50 mmol / L of guaifenesin and 2 mmol / L to 20 mmol / L of 2-morpholineethanesulfonic acid; the second component comprises a strong alkali solution, and the concentration of strong alkali in the strong alkali solution is 5 mol / L-20 mol / L. Specific acetylcysteine, guaifenesin and 2-morpholinoethanesulfonic acid are matched for use according to a specific proportioning relation, so that a viscous biological sample is quickly and sufficiently liquefied at room temperature, and the repeatability is relatively high. And the sample treated by the first component and the second component of the liquefied combined product prevents the strong acidity in the first component from interfering with the subsequent nucleic acid detection result.
A conjugate for treating an individual suffering from a disease, wherein the conjugate is comprised of: a targeting peptide comprising a sequence substantially identical to CAR, or a variant thereof; and at least one therapeutic molecule and methods for making and administering same. Also disclosed is a combination product for use in the treatment of a disease, wherein the combination product comprises: (a) a targeting peptide comprising a sequence substantially identical to CAR, or a variant thereof; (b) a liposome, wherein the targeting peptide is encapsulated within the liposome; and (c) an effective amount of an anti-inflammatory agent and methods for making and administering same.
This application belongs to the field of molecular biology technology, specifically relating to nucleic acid combinatorial products, kits for identifying Mycobacteriumtuberculosis complexes and detecting drug resistance gene mutations, and their applications. This application provides a nucleic acid combinatorial product for tNGS detection of Mycobacteriumtuberculosis complexes and related drug resistance genes, comprising at least one pair of primers selected from the nucleotide sequences shown in SEQ ID NO.1 to SEQ ID NO.344. Through optimized primer design, this product significantly improves multiplex PCR amplification efficiency and detection sensitivity. Compared to other NGS technologies such as single-molecule sequencing, this product significantly reduces detection costs while ensuring comprehensive detection, and can complete the entire analysis process from sample processing to result reporting within 24 hours. Furthermore, this nucleic acid combinatorial product also has species identification capabilities, accurately distinguishing Mycobacteriumtuberculosis complexes and their species and variant levels, thereby achieving synergistic improvements in detection breadth, cost, timeliness, and identification accuracy.
The present invention relates to a combination product, composition(s) and kit of parts comprising at least (i) a therapeutic vaccine and (ii) one or more immune checkpoint modulator(s). The present invention also concerns a method for treating a proliferative or an infectious disease as well as a method for eliciting or stimulating and / or re-orienting an immune response, wherein said methods comprise administering to a subject in need thereof said combination product or said composition(s).